CERT Certara, Inc.

Nasdaq certara.com


$ 8.34 $ 0.10 (1.22 %)    

Friday, 14-Nov-2025 11:19:48 EST
QQQ $ 610.44 $ 10.92 (1.82 %)
DIA $ 472.20 $ 0.78 (0.17 %)
SPY $ 673.00 $ 7.55 (1.13 %)
TLT $ 89.13 $ -0.66 (-0.74 %)
GLD $ 376.97 $ 4.08 (1.09 %)
$ 8.41
$ 8.22
$ 8.32 x 27
$ 8.34 x 60
$ 8.20 - $ 8.37
$ 8.13 - $ 15.69
2,466,986
na
1.34B
$ 1.50
$ 123.15
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 02-26-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 03-01-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bmo-capital-initiates-coverage-on-certara-with-market-perform-rating-announces-price-target-of-9

BMO Capital analyst Sean Dodge initiates coverage on Certara (NASDAQ:CERT) with a Market Perform rating and announces Price ...

 barclays-maintains-overweight-on-certara-lowers-price-target-to-14

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $16 to $14.

 certara-raises-fy2025-adj-eps-guidance-from-042-046-to-045-047-vs-044-est-narrows-fy2025-sales-guidance-from-415000m-425000m-to-415000m-420000m-vs-421766m-est

Certara (NASDAQ:CERT) raises FY2025 Adj EPS guidance from $0.42-$0.46 to $0.45-$0.47 vs $0.44 analyst estimate. Narrows FY2025 ...

 certara-q3-adj-eps-014-beats-011-estimate-sales-104616m-miss-104787m-estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 28.4...

 keybanc-maintains-overweight-on-certara-raises-price-target-to-16

Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and raises the price target from $15 to $16.

 craig-hallum-initiates-coverage-on-certara-with-buy-rating-announces-price-target-of-16

Craig-Hallum analyst Matthew Hewitt initiates coverage on Certara (NASDAQ: CERT) with a Buy rating and announces Price Targe...

 ubs-maintains-buy-on-certara-lowers-price-target-to-15

UBS analyst Dan Leonard maintains Certara (NASDAQ:CERT) with a Buy and lowers the price target from $17.5 to $15.

 certara-affirms-fy2025-adj-eps-guidance-of-042-046-vs-046-est-affirms-fy2025-sales-guidance-of-415000m-425000m-vs-421108m-est

Certara (NASDAQ:CERT) affirms FY2025 Adj EPS guidance from $0.42-$0.46 to $0.42-$0.46 vs $0.46 analyst estimate. Affirms FY2025...

 certara-q2-adj-eps-007-misses-010-estimate-sales-104600m-beat-104140m-estimate

Certara (NASDAQ:CERT) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.10 by 30...

 certara-achieves-ema-qualification-for-simcyp-enabling-biosimulation-in-drug-submissions-without-re-establishing-platform-credibility

With this qualification in place, sponsors can now use the Simcyp Simulator in regulatory submissions across the EU to assess d...

 keybanc-maintains-overweight-on-certara-lowers-price-target-to-15

Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $18 to $15.

 morgan-stanley-assumes-certara-at-equal-weight-announces-price-target-of-16

Morgan Stanley analyst Sean Laaman assumes Certara (NASDAQ:CERT) with a Equal-Weight rating and announces Price Target of $16.

 barclays-upgrades-certara-to-overweight-raises-price-target-to-14

Barclays analyst Luke Sergott upgrades Certara (NASDAQ:CERT) from Equal-Weight to Overweight and raises the price target fro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION